VT
ACAD icon

Vise Technologies’s Acadia Pharmaceuticals ACAD Stock Holding History

Vise Technologies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,367
Closed -$328K – 1462
2025
Q3 		$328K Buy
15,367
+585
+4% +$13.8K 0.01% 846
2025
Q2 		$319K Buy
+14,782
New +$275K 0.01% 821
2024
Q4 		$292K Sell
15,904
-353
-2% -$5.7K 0.02% 606
2024
Q3 		$250K Sell
16,257
-905
-5% -$15.1K 0.03% 510
2024
Q2 		$279K Buy
+17,162
New +$277K 0.05% 330

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Vise Technologies's ACAD Position: Q4 2025 in Review

Vise Technologies sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 15,367 shares — an estimated $328K sold.

Vise Technologies first reported a position in ACAD in Q2 2024 and held it in 5 quarters. The position peaked at $328K in Q3 2025. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Vise Technologies reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Vise Technologies sold 15,367 Acadia Pharmaceuticals shares in Q4 2025, an estimated $328K.
  • Vise Technologies first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Vise Technologies's Acadia Pharmaceuticals position peaked at $328K in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Vise Technologies's 13F filing for Q4 2025, filed 11 Feb 2026.